OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
February 27, 2024
Epkinly (epcoritamab-bysp), a subcutaneously administered, T-cell engaging, bispecific antibody, was previously granted Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory follicular lymphoma following two or more prior lines of therapy.
February 26, 2024
A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.
The company’s cloud technology services aim to assist healthcare and pharma with AI integration.
Xolair was approved last week to reduce allergic reactions from exposure to one or more food allergens in individuals over 1 year of age with IgE-mediated food allergy.
Bayer's BAY 2927088 is under evaluation to treat unresectable or metastatic non-small cell lung cancer with tumors harboring activating HER2 mutations.
February 23, 2024
A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.
SKYTyphoid, a single-dose typhoid conjugate vaccine jointly developed by SK bioscience and the International Vaccine Institute, showed a positive immunogenicity and safety profile across age groups.
The CRO’s FortreaRx doubles in size, including a boost in cold chain storage, while also continuing to improve its patient access services.
Trial data show Dupixent is the first and only novel biologic drug to significantly improve lung function and reduce severe acute exacerbations in adults with uncontrolled chronic obstructive pulmonary disease.
The latest news for pharma industry insiders.